Profit pressure from higher manufacturing costs at overseas subsidiaries
First written in FY2023-Q2. 6 of 9 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025RestatedAnnual report
「Cost of sales increased due to higher manufacturing costs, including materials and labor costs, at overseas production subsidiaries, as well as the disposal of slow-moving inventory, which resulted in a ¥98 million charge.」
Higher materials and labor costs at overseas production subsidiaries continue to be cited as cost factors, and the company also disclosed a ¥98 million impact from the disposal of slow-moving inventory. - FY2025-H1RestatedAnnual report
「Cost of sales was ¥5,317 million, up 2.0% year on year, due to higher manufacturing costs at production subsidiaries, among other factors,」
The company states that higher manufacturing costs at production subsidiaries continue to drive the increase in cost of sales. - FY2024WorsenedAnnual report
「Cost of sales was ¥10,616 million, up 17.1% year on year, due to higher manufacturing costs at overseas subsidiaries, among other factors, and the cost-of-sales ratio deteriorated by 0.2 percentage points from the previous fiscal year.」
Higher manufacturing costs at overseas subsidiaries were reflected in the 17.1% full-year increase in cost of sales and the 0.2-percentage-point deterioration in the cost-of-sales ratio. - FY2024-Q3WorsenedAnnual report
「Meanwhile, cost of sales was ¥8,001 million, up 11.2% year on year, due to higher manufacturing costs at overseas subsidiaries, among other factors.」
Higher manufacturing costs at overseas subsidiaries continue to drive the increase in cost of sales, which rose 11.2% year on year. - FY2024-Q2RestatedAnnual report
「Meanwhile, cost of sales was ¥5,213 million, up 7.6% year on year, due to higher manufacturing costs at overseas subsidiaries, among other factors.」
Higher manufacturing costs at overseas subsidiaries continue to be cited as a factor behind the 7.6% year-on-year increase in cost of sales in cumulative FY2024-Q2. - FY2024-Q1RestatedAnnual report
「Meanwhile, cost of sales was ¥2,667 million, up 8.6% year on year, due to higher manufacturing costs at overseas subsidiaries, among other factors.」
Higher manufacturing costs at overseas subsidiaries continue to be cited as a factor behind the 8.6% year-on-year increase in cost of sales in FY2024-Q1. - FY2023RestatedAnnual report
「Meanwhile, cost of sales was ¥9,066 million, up 15.6% year on year, due to higher manufacturing costs at overseas subsidiaries, among other factors.」
Higher manufacturing costs at overseas subsidiaries continue to drive the increase in cost of sales. Meanwhile, operating profit increased as the rise in sales outpaced the increase in expenses. - FY2023-Q3RestatedAnnual report
「Meanwhile, cost of sales was ¥7,193 million, up 24.2% year on year, due to higher manufacturing costs at overseas subsidiaries, among other factors.」
Higher manufacturing costs at overseas subsidiaries continue to drive the increase in cost of sales. Segment profit for surgical-related products fell 2.7% year on year due to higher manufacturing-related expenses, among other factors. - FY2023-Q2First statedAnnual report
「Cost of sales was ¥4,843 million, up 31.4% year on year, due to increased sales and higher manufacturing costs at overseas subsidiaries, among other factors.」
Higher manufacturing costs at overseas subsidiaries were reflected in the 31.4% year-on-year increase in cost of sales. Segment profit for surgical-related products fell 5.8% year on year due to higher manufacturing-related expenses, among other factors.